As you know, Strep. uberis is now the most common infectious agent isolated from milk samples
submitted to the VLA regional labs.1 Strep. uberis leads to high somatic cell counts (SCC)
and clinical mastitis that is difficult to cure.2 And both are associated with substantial economic loss.Best practice - which improves clinical outcomes - requires a diagnostic test. Identifying the pathogen allows targeted antimicrobial therapy and improves control of the pathogen in the herd.
In acute clinical cases, where immediate treatment is necessary, sampling is still valuable because improved understanding of the infectious agents in the herd helps make future management more specific and therefore more efficient.

udder
mamyzin injection


Once Strep. uberis has been confirmed, treatment with Mamyzin continues best practice. Strep. uberis is particularly vulnerable to Mamyzin. Partly because Mamyzin concentrates preferentially, where it's needed, in the udder.3 Resistance in the UK is rare,2 consequently cure rates are very high and SCCs decline rapidly. This, and the fact that all quarters are treated at once, makes Mamyzin the kind of smart weapon many of you have been seeking, for use against Strep uberis. Together we can do what's best for herds. This, after all, is in everyone's best interests.

For printable information the monograph can be downloaded here in adobe acrobat format


mamyzin injection

Boehringer Ingelheim UK websites:
Corporate: Boehringer Ingelheim UK, Boehringer Ingelheim Corporate Site
Consumer Health Care: Antistax, Dulcolax, Healthy Legs, IBS Relief, Constipation facts, Pass it On, Dulcoease
Animal Health: Vetmedin, Metacam, Ingelvac Myho, Mamyzin, Seraquin
Access to and use of this website is subject to our Terms of use which users are deemed to accept by accessing this website.
(c) 2007 Boehringer Ingelheim Ltd UK. All rights reserved. Company Registration Number: 711858 England & Wales
Boehringer Ingelheim Limited, Registered Office, Ellesfield Avenue, Bracknell, Berks RG12 8YS